ALT
Altimmune Inc.
$5.27
-$0.07(-1.31%)
56
Overall
60
Value
66
Tech
42
Quality
Market Cap
$575.48M
Volume
6.36M
52W Range
$2.90 - $9.59
Target Price
$17.88
Company Overview
| Mkt Cap | $575.48M | Price | $5.27 |
| Volume | 6.36M | Change | -1.31% |
| P/E Ratio | -6.1 | Open | $5.40 |
| Revenue | $20.0K | Prev Close | $5.34 |
| Net Income | $-95.1M | 52W Range | $2.90 - $9.59 |
| Div Yield | N/A | Target | $17.88 |
| Overall | 56 | Value | 60 |
| Quality | 42 | Technical | 66 |
No chart data available
About Altimmune Inc.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Sector: Healthcare
Industry: Biotechnology
Latest News
ALT5 Sigma CEO Departure and Transition Agreement
TipRanks Auto-Generated Newsdesk•a day ago
ALT5 Sigma Settles Multiple Legal Disputes
TipRanks Auto-Generated Newsdesk•a day ago
MicroSalt plc Successfully Completes Retail Offer, Strengthening Growth Prospects
TipRanks UK Auto-Generated Newsdesk•2 days ago
MicroSalt Launches Retail Offer to Bolster Financial Position
TipRanks UK Auto-Generated Newsdesk•5 days ago
MicroSalt plc Raises £1.5 Million to Boost Production and Growth
TipRanks UK Auto-Generated Newsdesk•5 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ALT | $5.27 | -1.3% | 6.36M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |